Changing priorities in Hodgkin's disease C J WILLIAMS Despite greatly improved survival rates for patients with Hodgkin's disease its management has become complex and continues to evolve. Ten years ago order was brought into the management of Hodgkin's disease by introducing lymphangiography of the legs,' staging laparotomies,2 extended field radiotherapy using megavoltage equipment,3 and effective combination chemotherapy.4 Now, however, there is pressure to abandon "conventional" management based on these principles.
Staging laparotomies2 increased our knowledge of the natural history of Hodgkin's disease and allowed the introduction of an effective staging classification. These borderline survival advantages in symptom-free patients have taken 10 years to appear and are the result of a prolonged and difficult treatment regimen. In addition to the immediate toxicity the treatment has produced sterility in men'7 and is associated with secondary malignancies."" 19 As extensive radiotherapy may not be required in combination with chemotherapy these studies were discontinued in 1974 and new studies were started in which radiotherapy of the affected areas and chemotherapy were compared with subtotal lymphoid irradiation. A preliminary paper20 at five years reported excellent survival and freedom from relapse in both groups in this study, but longer observation is required.
Since the introduction of adjuvant chemotherapy for stages I-III some have suggested that such patients might be treated with chemotherapy alone. A preliminary report2l of a study comparing chemotherapy and radiotherapy with chemotherapy alone was made last year. Of 13 patients who received chemotherapy alone three were reported to have relapsed (confirmed by personal communication), although when the abstract was prepared only one had. The British National Lymphoma CRC Medical Oncology Unit, Southampton General Hospital, Southampton S094XY C J WILLIAMS, MB, MRCP senior lecturer Group22 have compared chemotherapy with total lymphoid irradiation in stage IIIA patients. Although the initial complete remission rate and disease-free survival was inferior in the chemotherapy group, there was no difference in overall survival and longer follow-up is necessary. Chemotherapy alone for early-stage disease remains experimental, and such results should discourage its use until it has been thoroughly evaluated in controlled studies.
Problem of secondary malignancies
Recent studies have highlighted the problem of secondary malignancies in patients treated for Hodgkin's disease. In the Stanford series18 the actuarial estimate of the incidence of acute non-lymphoblastic leukaemia at seven years for patients receiving irradiation and chemotherapy was 3 9%. The high incidence of leukaemias in patients receiving both chemotherapy and irradiation is seen in other large studies23 24 Hodgkin's disease, has become a complicated problem of management that is best treated in specialist centres possessing experience in the many branches of medicine needed for optimal care. Despite advances, new clinical trials are still needed to refine treatment further. The main challenges are to define subgroups of patients who will benefit from combined-modality treatment, to reduce the acute toxicity of chemotherapy, to reduce the long-term effects of chemotherapy (especially second malignancies and sterility), and to design more effective chemotherapy regimens for patients who fail to respond to standard treatment. Answers to the questions can be obtained only from controlled studies testing the initial management, the effectiveness of salvage after relapse, and assessing the longterm toxicities of new treatments.27
